InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Investor Presentation (May 2024)
20 slides from InMed Pharmaceuticals's investor presentation, May 2024
Slide 1: Corporate Presentation
Corporate Presentation May 2024 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: Overview & Investment Highlights
Overview & Investment Highlights • Robust R&D pipeline with 3 candidates in dermatology, ocular and Alzheimer’s • A successful Phase 2 dermatology program, currently seeking partnerships • Library of proprietary analogs targeting diverse pharmaceutical applications • A revenue generating subsidiary
Slide 4: A Clinical Stage Pharmaceutical Company
A Clinical Stage Pharmaceutical Company A GLOBAL LEADER IN THE RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF RARE CANNABINOIDS Drug Discovery Pharmaceutical R&D Manufacturing Commercial • Pipeline of pharmaceutical programs • Screening of therapeutic • Chemical and • B2B supplier to
Slide 5: Drug Development Programs
Drug Development Programs Focused on developing a pipeline of proprietary small molecule drug candidates
Slide 6: Pharmaceutical Pipeline
Pharmaceutical Pipeline HIGHLIGHTS SCREENING PRECLINICAL PH 1 PH 2 PH 3 NATURALLY-OCCURRING CANNABINOIDS • Phase 2 - Study completed • Showed a positive indication of enhanced INM-755 CBN anti-itch activity versus control cream Seeking Strategic Partnerships Epidermolysis bullosa • Currently pursuin
Slide 7: INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch
INM-755 Cannabinol (CBN) Cream: Phase 2 Results in Itch Conducted in Epidermolysis bullosa patients – a severe genetic dermatological disease with chronic, severe itch as a primary sumptom. Key Results: Non-Wound Itch: Data breakdown Of the 18 participants assessed, chronic itch improved by a • A po
Slide 8: INM-089 in Dry Age-related Macular Degeneration
INM-089 in Dry Age-related Macular Degeneration CBN ANALOG DEMONSTRATED PROMISING EFFECTS RELATED TO THE TREATMENT OF AMD Unmet medical need AMD market AMD causes damage to the retina at the back of eye. Currently, there are no approved treatments for people with dry age-related macular degeneration
Slide 9: Alzheimer's Disease – Unmet Medical Need is High
Alzheimer’s Disease – Unmet Medical Need is High CANNABINOIDS MAY OFFER A NEW MULTIPRONGED APPROACH Unmet medical need Medications to treat Alzheimer’s target individual disease Market components and may slow the rate of cognitive decline but Nearly 7 million Americans are living with none have been
Slide 10: Alzheimer's Disease – Multiple Mechanisms of Action
Alzheimer’s Disease – Multiple Mechanisms of Action • Preferential signaling agonist of cannabinoid receptor 1 (CB1), cannabinoid receptor 2 (CB2) • Impacts the peroxisome proliferator-activated receptor (PPAR) signaling pathway. INM-901 INM-901 Cytotoxicity Inflammation Neuroprotection Other featur
Slide 11: INM-901 demonstrates promising effects in validated in vivo Alzheimer's disease models
INM-901 demonstrates promising effects in validated in vivo Alzheimer’s disease models POTENTIAL TO TARGET SEVERAL BIOLOGICAL PATHWAYS ASSOCIATED WITH ALZHEIMER’S DISEASE Neuroprotection Neuritogenesis ALZ Behavioral Studies Studies Studies • Amyloid-β-induced model • Neurite length • Basal and loco
Slide 12: A Diverse Patent Portfolio
A Diverse Patent Portfolio 13 PATENT FAMILIES – NCEs/Formulations, Manufacturing Methods, Methods of Use NCEs Manufacturing Methods of use 2 patent families filed 7 patent families filed 4 patent families filed • 21 international pending • 2 granted • 2 granted • 29 international pending • 22 intern
Slide 13: BayMedica Commercial Business
BayMedica Commercial Business
Slide 14: BayMedica - Wholesale Rare Cannabinoids for the H&W Market
BayMedica -Wholesale Rare Cannabinoids for the H&W Market HIGH PURITY, CONSISTENT & BIOIDENTICAL TO NATURE CBC CBDV THCV CBT Cannabichromene Cannabidivarin Tetrahydrocannabivarin Cannabicitran CONSISTENCY COST-EFFECTIVENESS High quality, bioidentical rare cannabinoids with exceptional Multiple manuf
Slide 15: BayMedica Financial Performance
BayMedica Financial Performance Fiscal Year Revenue Growth US$ (Fiscal year ends June 30) (000’s) • 278% growth: YoY 2023 v 2022 2,500 $2.3M • Trailing 12-month revenue is $5.6m 2,000 • Currently operating as a cash flow positive business 1,500 $1.2M $1.2M • Quarterly fluctuations due to inconsisten
Slide 16: Corporate
Corporate
Slide 17: Depth in Pharmaceutical R&D
Depth in Pharmaceutical R&D EXTENSIVE EXPERIENCE IN PHARMA DISCOVERY, DEVELOPMENT, API MANUFACTURING, CLINICAL AND REGULATORY Eric A. Adams, MIBS Neeta Jagpal, CPA Alexandra Mancini, MSc Jerry P. Griffin Shane Johnson, MD Chief Executive Officer Chief Financial Officer SVP, Clinical & Regulatory Aff
Slide 18: Financial Snapshot
Financial Snapshot As of 2024-05-22 Cash and Short-term Investments $9.5 M(1) Shares I/O 9.6 M(2) Options 0.6 M Warrants and Preferred Investment Options (9.6M @$0.83 cents) 10.2 M Fully Diluted Shares 20.4 M Close US$0.33 52-week High US$2.08 52-week Low US$0.23 Avg. Daily Volume (Trailing 50 Days)
Slide 19: Fiscal 2024 – Key Value Drivers
Fiscal 2024 – Key Value Drivers • Advance INM-901 in ALZ in long-term preclinical in vivo studies and manufacturing • Advance INM-089 in Dry AMD towards IND filing / human clinical trials • Evaluate INM-755 in itch for clinical and commercial partnerships • Target proprietary cannabinoid analogs for
Slide 20: Thank you!
UNLOCKING THE POTENTIAL OF CANNABINOID MEDICINES Thank you! Colin Clancy Vice President, Investor Relations & Corporate Communications [email protected] +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (May 2024) on 6ix